New €9m vaccine project to combat AMR with big data and AI
A new European consortia called PrIMAVeRA is developing an open-source, web-based platform combining mathematical models with an epidemiological repository to inform decision makers about the most efficient use of vaccines or mAbs.
Vaccines and monoclonal antibodies (mAb) (molecules engineered to mimic the immune response towards harmful pathogens) can play an important role in the fight against antimicrobial resistance because they are not sensitive to the inevitable obsolescence of antimicrobials. However, no comprehensive data-driven tools are available until now to inform decisions about the most efficient use of vaccines, as well as mAbs, in the fight against antimicrobial resistance. Research and development of vaccines and mAbs against resistant pathogens has consequently suffered a lack of financial investment, therefore increasing the burden of AMR.
The Innovative Medicines Initiative 2 (IMI2) called to life PrIMAVeRa, which is a new European public private partnership aimed at developing an open-source, web-based platform combining mathematical models with an epidemiological repository (i.e., that stores data relating to health and economic outcomes). With the help of this database, policymakers will be able to make data-driven decisions regarding prioritization of specific vaccines and monoclonal antibodies, informing the strategic allocation of resources.
PriMAVeRa involves 19 partners across the EU, the UK and Russia, including 16 academic institutions and SME as well as GSK, Pfizer and Janssen as industry partners. It is coordinated by the European Vaccine Initiative (Germany), with the support of Professor Marc Bonten of the University Medical Center Utrecht (Netherlands) as scientific coordinator, and GSK as the industry lead. The consortia is now part as a further project of the IMI AMR Accelerator.